PharmaJet Partner Zydus Cadila Announces Emergency Use Authorization Approval for World’s First Plasmid DNA COVID-19 Vaccine
23.8.2021 16:05:00 EEST | Business Wire | Press release
PharmaJet ®, the maker of innovative, needle-free injection technology, today announced that its partner, Zydus Cadila, has received the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D the world’s first Plasmid DNA Vaccine for COVID-19. The vaccine, ZyCoV-D, is exclusively administered using the PharmaJet Tropis® Needle-free Injection System.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210823005175/en/
The COVID-19 vaccine is exclusively administered using the PharmaJet Tropis Needle-free Injection System. (Photo: Business Wire)
Speaking on this development, Mr. Pankaj R. Patel, Chairman, Cadila Healthcare Ltd., said, “This is an historic milestone with ZyCoV-D, a product of Indian innovation becoming the world’s first DNA vaccine being offered for human use and supporting the world’s largest immunization drive. We are particularly happy that our vaccine will contribute to this fight against COVID-19 and enable the country to vaccinate a larger population especially in the age group of 12-18 years. I would like to thank all the researchers, clinical trial investigators, volunteers and the regulators who have supported this endeavor.”
The DCGI decision is based on data from a pivotal phase 3 clinical trial which enrolled over 28,000 volunteers. Included in the trial were adolescents in the 12-18 age group, a first for a COVID-19 vaccine trial in India. ZyCoV-D exhibited robust immunogenicity, tolerability, and safety.
Chris Cappello, President and CEO, PharmaJet, said, “We congratulate our partner Zydus Cadila for achieving this critical milestone. The Emergency Use Authorization (EUA) is a huge step forward to help in the eradication of COVID-19. It demonstrates the power of DNA-based vaccines and broadens the use of needle-free jet injection. We are proud to be part of the development and commercialization of the first ever plasmid-based DNA vaccine.”
For more information about PharmaJet visit www.pharmajet.com.
Refer to Instructions for Use to ensure safe injections and to review risks.
1 Data on file
About PharmaJet
PharmaJet’s mission is to improve people’s lives through needle-free technology. PharmaJet Needle-free Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. For more information visit www.pharmajet.com.
Zydus’ Vaccine research program
The Vaccine Technology Centre of Zydus Cadila has a wide range of capabilities in developing and manufacturing viral, toxoid, polysaccharide, conjugate, and other subunit vaccines for unmet needs. In fact, Zydus was the first company in India to develop and indigenously manufacture the vaccine to combat Swine Flu during the pandemic in 2010. In the past, it has also indigenously developed numerous vaccines successfully including tetravalent seasonal influenza vaccine (first company in India to indigenously develop and commercialize), Inactivated Rabies vaccine (WHO Prequalified), Varicella vaccine (first Indian company to indigenously develop and receive market authorization), Measles containing vaccines (MR, MMR, Measles), Typhoid conjugate vaccine, pentavalent vaccine (DPT-HepB-Hib) etc. to name a few. The company also has a strong pipeline of vaccines like Measles-Mumps-Rubella-Varicella (MMRV), Human papillomavirus vaccine, Hepatitis A, Hepatitis E vaccines which are at various stages of development. For more information, visit https://zyduscadila.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210823005175/en/
Contact information
Nancy Lillie
Nancy.Lillie@pharmajet.com
1-888-900-4321 Option 3
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kept Alive by ECMO Until Heart Transplant: Sahara Romero's Story of Survival and Recovery, with ECMOlife by Eurosets12.5.2026 11:45:00 EEST | Press release
“Now, for the first time in years, I can live without constantly fearing something could go wrong.” That's how Sahara Romero told her story, presented at the EuroELSO Congress in Dublin (6-8 May), dedicated to lifesaving extracorporeal therapies. Hers is a remarkable journey back to life, where clinical expertise and advanced life-support technologies came together to radically change her fate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511305446/en/ Antonio Petralia, CEO of Eurosets; Sahara Romero, patient; dr. Mario Andrés Mercado Díaz, Intensive care specialist at the Clínica Shaio in Bogotá; Estefanía Giraldo Bejarano, specialist ECMO nurse at the Clínica Shaio in Bogotá Sahara has lived with a serious heart condition since early adolescence. The first signs of heart failure appeared when she was eleven. “When I was doing simple activities, like gymnastics lessons, I got very tired and experienced pain in my chest
New Research From Infobip Finds Disconnected Data and Systems Prevent Brands From Automating Customer Journeys at Scale12.5.2026 11:39:00 EEST | Press release
Global AI-first cloud communications platform Infobip’s 2026 Customer Experience (CX) Maturity Report reveals a widening gap between communications infrastructure investment and CX performance. With ever-increasing customer expectations, achieving CX maturity is the goal for major global brands. This hinges on how well brands can build experiences on mobile channels. There is a fundamental difference between a simple fraud alert on SMS and a two-way WhatsApp chat that allows customers to act immediately. While 96% of brands automate customer interactions in some way, few are delivering a seamless experience. Only 58% of brands say their channels are fully in sync, and 60% have centralized storage of customer data. But looking closer, only 27% use an orchestration platform, and 50% of brands say their tools are fully API-ready. This means half of brands struggle with connecting tools and data and many don't use a unified platform to build truly seamless experiences. This fragmentation i
Rerouting Alone Could Cost Airlines $8 Billion This Summer, New i6 Group Data Shows12.5.2026 11:00:00 EEST | Press release
Airlines flying European long-haul routes are facing a fuel cost penalty that could exceed $8 billion between May and August 2026, according to a new operational data report released today by i6 Group, a global leader in integrated aviation fuel management technology. The report, “Middle East Conflict: Summer 2026 Outlook,” draws on real fueling transactions captured at nearly 300 airports worldwide by i6's Fusion6 platform and provides insight into the costs of the conflict so far and how it might impact summer travel, based on actual fuel supply and into-plane uplift data. Key Findings $5.6 billion – $8.4 billion: Projected industry-wide rerouting fuel cost, May–August 2026 62.2%: Increase in European airport fuel book stocks (April 2026 vs. April 2025) 415,373 tons: Additional CO2 generated monthly from rerouting in the i6 network alone, or the equivalent of nearly 6,000 extra London–New York round-trip flights per month "The data captures what airlines are paying to fly around clos
Paymentology Raises $175 Million co-led by Apis Partners and Aspirity Partners to Support Next Phase of Growth12.5.2026 10:01:00 EEST | Press release
Paymentology, the leading global issuer-processor, today announced a $175 million investment co-led by Apis Partners (”Apis”), a private equity firm specialising in financial infrastructure and services, and Aspirity Partners (“Aspirity”), a pan-European Private Equity firm focused on Financial Technology & Services and Enterprise Technology & Connectivity Services. The investment will support Paymentology’s continued global expansion, product development and strengthening of its team, as the company builds on strong demand for modern issuer processing on a global scale. The transaction brings together two investors with deep experience in the payments industry and a shared focus on advancing payments infrastructure, united by the view that issuer processing represents one of the most significant opportunities in the sector. For Apis, the investment, made by Apis Growth Fund III1, marks the firm’s 16th payments investment. Both Apis and Aspirity will draw on their deep sector and globa
IQM Launches HPC Integration Service to Accelerate Hybrid Quantum-HPC Adoption12.5.2026 10:00:00 EEST | Press release
IQM Quantum Computers today launched HPC Integration Service, a turnkey solution that enables its IQM Radiance quantum computers to operate as a slurm node inside high-performance computing (HPC) environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512187465/en/ IQM Radiance quantum computer (right) co-located with classical HPC infrastructure (left) in a data center environment. Using this widely adopted HPC workflow, IQM aims at accelerating adoption of hybrid quantum-classical computing across enterprises and research institutions. Slurm is the open-source workload manager used by most of the world’s leading supercomputing centers for its scalability and flexibility. The integration service makes quantum a scheduled resource alongside central processing units (CPUs) and graphics processing units (GPUs), removing the integration work that has slowed adoption. In addition, the service is built on IQM´s Quantum Dev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom